Kahn Swick & Foti, LLC has initiated an investigation into the proposed sale of Penumbra, Inc. by examining whether the consideration of $374 per share in cash or 3.8721 shares of Boston Scientific stock properly reflects the company’s intrinsic value. Led by former Louisiana Attorney General Charles C. Foti, Jr., the firm is scrutinizing the negotiation process and timing of the deal announcement, to determine if Penumbra’s board fulfilled its fiduciary duties. Shareholders with concerns can contact KSF at no cost to discuss potential claims before the transaction closes in 2026.

Following the acquisition announcement, BTIG downgraded Penumbra from Buy to Neutral, signaling that the 19% premium embedded in Boston Scientific’s bid may not fully compensate for execution and integration risks. The analyst noted that while the deal, valued at approximately $14.5 billion, would be Boston Scientific’s largest in over twenty years, the large debt load required to finance the transaction and potential overlap in product lines could temper long-term synergies.

Penumbra’s shares jumped 11.8% in the session after deal details emerged, driven by heavier-than-average volume as institutional investors reshuffled positions. Several sell-side strategists have since raised full-year revenue and earnings estimates by roughly 3% and 5%, respectively, reflecting anticipated benefits from planned product launches in neurovascular thrombectomy and embolization procedures. Market participants will be watching liquidity trends and trading spreads for clues on whether this strength can be sustained through shareholder voting later in the year.